| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively expanding patient access
BRISBANE, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic collaboration1 with Johnson & Johnson MedTech to significantly expand the market reach of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), leveraging its specialized early intervention sales force to co-promote the treatment to existing and new customers. ZILRETTA is Pacira's extended-release treatment for osteoarthritis knee pain. This agreement is expected to significantly expand access and extend reach across a large portion of the seven million intra-articular knee injections administered to patients annually in the U.S.
Posted In: PCRX
